Infliximab was discontinued ( after a median of @ mo ) in @ out of @ patients for loss of response ( n = @ -LSB- @ % -RSB- ) , intolerance ( n = @ -LSB- @ % -RSB- ) , or non-compliance ( n = @ -LSB- @ % -RSB- ) .